311 related articles for article (PubMed ID: 28595433)
21. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
De Tursi M; Carella C; Tomao S; Cinieri S; Lorusso V; Marchetti P; Vecchio S; Sansoni E; Contu A; Adamo V; Silvestris N; Nuzzo A; Rosti G; Ravaioli A; Danova M; Tonini G; Passalacqua R; Cruciani G; Faedi M; Spada M; De Laurentiis M; Amoroso D; Tomao F; Sperduti I; Grassadonia A; Tinari N; Natoli C; Iacobelli S;
Tumori; 2014; 100(6):e309-13. PubMed ID: 25688518
[TBL] [Abstract][Full Text] [Related]
23. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
24. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
25. Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals.
McKinnon K; Jupp J; Ghosh S; Digout C; Eason S; Romanick M
Pediatr Blood Cancer; 2019 Jan; 66(1):e27488. PubMed ID: 30318842
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
Kottschade L; Novotny P; Lyss A; Mazurczak M; Loprinzi C; Barton D
Support Care Cancer; 2016 Jun; 24(6):2661-7. PubMed ID: 26768436
[TBL] [Abstract][Full Text] [Related]
27. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy.
Pillai AK; Sharma KK; Gupta YK; Bakhshi S
Pediatr Blood Cancer; 2011 Feb; 56(2):234-8. PubMed ID: 20842754
[TBL] [Abstract][Full Text] [Related]
28. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
Craver C; Gayle J; Balu S; Buchner D
J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
[TBL] [Abstract][Full Text] [Related]
29. Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy.
Yokoi M; Tsuji D; Suzuki K; Kawasaki Y; Nakao M; Ayuhara H; Kogure Y; Shibata K; Hayashi T; Hirai K; Inoue K; Hama T; Takeda K; Nishio M; Itoh K
Support Care Cancer; 2018 May; 26(5):1505-1513. PubMed ID: 29177570
[TBL] [Abstract][Full Text] [Related]
30. Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain.
Escobar Álvarez Y; De Castro Carpeño J; Bell D; Drago A; Franceschetti A
Clin Transl Oncol; 2021 Oct; 23(10):2155-2162. PubMed ID: 33956310
[TBL] [Abstract][Full Text] [Related]
31. Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study.
Lee MA; Cho EK; Oh SY; Ahn JB; Lee JY; Thomas B; Jung H; Kim JG
Cancer Res Treat; 2016 Oct; 48(4):1420-1428. PubMed ID: 26875197
[TBL] [Abstract][Full Text] [Related]
32. Platinum-induced nausea and vomiting in patients treated for head and neck cancer.
Rambeau A; Cherifi F; Neviere Z; Licaj I; Clarisse B; Joly F
Bull Cancer; 2021 May; 108(5):449-454. PubMed ID: 33814187
[TBL] [Abstract][Full Text] [Related]
33. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.
Burke TA; Wisniewski T; Ernst FR
Support Care Cancer; 2011 Jan; 19(1):131-40. PubMed ID: 20101417
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Ng WL; Della-Fiorentina SA
Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
[TBL] [Abstract][Full Text] [Related]
36. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
37. Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate.
Vol H; Flank J; Lavoratore SR; Nathan PC; Taylor T; Zelunka E; Maloney AM; Lee Dupuis L
Support Care Cancer; 2016 Mar; 24(3):1365-71. PubMed ID: 26335406
[TBL] [Abstract][Full Text] [Related]
38. Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report.
Mantovani G; Curreli L; Macciò A; Massa E; Massa D; Mulas C; Succu G; Contu P
Anticancer Res; 1999; 19(4C):3495-502. PubMed ID: 10629642
[TBL] [Abstract][Full Text] [Related]
39. Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists.
Majem M; Moreno ME; Calvo N; Feliu A; Pérez J; Mangues MA; Barnadas A
Support Care Cancer; 2011 Dec; 19(12):1983-90. PubMed ID: 21086141
[TBL] [Abstract][Full Text] [Related]
40. Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
Anticancer Res; 2018 Feb; 38(2):877-884. PubMed ID: 29374715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
